pharmacokinetic studies of black-tailed prairie dogs

Closed Pre-Solicitation Posted

Solicitation number
PR94688
Agency
Responses due
Set-aside
Total Small Business

Opportunity facts

Place of performance
Atlanta, Georgia 30329, United States

Notice details come from SAM.gov. Updated .

About this opportunity

The Centers for Disease Control and Prevention (CDC) Office of Acquisition Services is seeking specialized laboratory services for pharmacokinetic studies involving black-tailed prairie dogs and Cast/EiJ mice. The procurement involves liquid chromatography tandem mass spectrography (LC-MS/MS) and pharmacokinetic sample analysis of two specific compounds: Alisporivir (Compound A) and Cyclophilin Inhibitor (NIM811) (Compound B) in mouse plasma samples. This research support falls under the CDC's Poxvirus and Rabies Branch and requires highly specialized analytical capabilities for unique species-specific assay development. The procurement is classified under NAICS code 541380 for Testing Laboratories and Services and PSC code AJ13 for General Science & Technology Research and Development Services. The pre-solicitation notice was posted on July 28, 2025, with a response deadline of August 12, 2025.

This opportunity is designated as a Total Small Business set-aside, though the attached sole source justification indicates the CDC intends to procure directly from NorthEast BioAnalytical Laboratories LLC. The justification document reveals that other potential vendors including Charles River Laboratories and Auburn University were contacted but could not meet the specialized analysis requirements for the unique species involved in the study. The sole source procurement is being justified under FAR 13.106-1(b)(1) for acquisitions under $250,000 where only one source is reasonably available. NorthEast BioLab has been identified as the only vendor capable and willing to develop the required assays for black-tailed prairie dogs and Cast/EiJ mice. The procurement supports ongoing scientific research requiring specialized pharmacokinetic analysis capabilities that are not readily available through standard laboratory service providers.

Notice text

See attached Notice of Intent

Files

File Type Posted
A13- Sole Source Justification - CO signed 30 Jul 2025_Redacted.pdf PDF
A22-NOI.pdf PDF

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors